Headlines

Scorpion Capital gives a negative call on Abivax (ABVX FP)

Newsquawk Staff ·

Scorpion Capital gives a negative call on Abivax (ABVX FP)

What it means

This is an activist short call rather than a conventional sell-side note, and the distinction matters for how it trades. Scorpion Capital operates in the short-seller research genre, publishing detailed negative theses while holding a financial interest in the stock's decline; comparable reports from firms in this niche have historically produced a sharp initial gap down in small and mid-cap names, followed by a partial retracement once the market digests the claims and the company issues a rebuttal. Single-asset biotech names like this one are particularly exposed to such reports because the valuation rests heavily on a narrow clinical and regulatory narrative, so any challenge to trial data integrity, disclosure practices, or commercial assumptions can compress the multiple quickly regardless of merit. The usual sequence is: the report circulates, the stock gaps, the company responds within days, and the follow-through depends on whether independent verification of the report's specific claims emerges. Worth watching are the substance of the allegations (data versus accounting versus governance behave differently), the company's formal reply, any regulatory interest, and borrow availability in the name. As with all such reports, the publisher's position is a standing caveat on objectivity.

Related headlines